The medical letter on drugs and therapeutics january 5 2015

In Brief: Influenza in 2015 Superseded by The Medical Letter "Influenza Vaccine for 2016-2017" - Issue 1505, October 10, 2016The CDC has announced that the most common influenza viruses circulating now are influenza A... Olodaterol (Striverdi Respimat) for COPD Olodaterol (Striverdi Respimat – Boehringer Ingelheim), a new inhaled long-acting beta2-agonist, has been approved by the FDA for once-daily maintenance treatment of airflow... Oritavancin (Orbactiv) for Skin and Skin Structure Infections The FDA has approved oritavancin (Orbactiv – The Medicines Company), a long-acting lipoglycopeptide antibiotic given as a single intravenous (IV) dose, for treatment of acute bacterial... Trumenba: A Serogroup B Meningococcal Vaccine The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young... Triumeq: A 3-Drug Combination for HIV The FDA has approved Triumeq (Viiv Healthcare), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleoside reverse transcriptase inhibitors... Siltuximab (Sylvant) for Treatment of Multicentric Castleman''s Disease (online only) The FDA has approved the interleukin-6 (IL-6) antagonist siltuximab (Sylvant – Janssen), a recombinant chimeric (human-mouse) monoclonal antibody, for treatment of multicentric...

The Medical Letter ® on Drugs and Therapeutics Objective Drug Reviews Since 1959 Volume 57 ISSUE ISSUE No 1433 1459 Volume 56 January 5, 2015 IN THIS ISSUE In Brief: Influenza in 2015 p Olodaterol (Striverdi Respimat) for COPD p Oritavancin (Orbactiv) for Skin and Skin Structure Infections p Trumenba: A Serogroup B Meningococcal Vaccine p Triumeq: A 3-Drug Combination for HIV p Siltuximab (Sylvant) for Treatment of Multicentric Castleman’s Disease online only Important Copyright Message FORWARDING OR COPYING IS A VIOLATION OF U.S AND INTERNATIONAL COPYRIGHT LAWS The Medical Letter, Inc publications are protected by U.S and international copyright laws Forwarding, copying or any distribution of this material is prohibited Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited By accessing and reading the attached content I agree to comply with U.S and international copyright laws and these terms and conditions of The Medical Letter, Inc For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769 Published by The Medical Letter, Inc • A Nonprofit Organization The Medical Letter publications are protected by US and international copyright laws Forwarding, copying or any other distribution of this material is strictly prohibited For further information call: 800-211-2769 The Medical Letter ® on Drugs and Therapeutics Objective Drug Reviews Since 1959 Volume 57 ISSUE ISSUE No 1433 1459 Volume 56 January 5, 2015 Take CME Exams ALSO IN THIS ISSUE Oritavancin (Orbactiv) for Skin and Skin Structure Infections p Trumenba: A Serogroup B Meningococcal Vaccine p Triumeq: A 3-Drug Combination for HIV p Siltuximab (Sylvant) for Treatment of Multicentric Castleman's Disease online only ▶ IN BRIEF Influenza in 2015 The CDC has announced that the most common influenza viruses circulating now are influenza A H3N2, which tend to cause more severe disease, and that about half of these viruses are antigenically different from the H3N2 strain in this year’s flu vaccine.1 Vaccination may still have a protective effect, even against drifted variants, and patients who have not received this year’s vaccine2 should be encouraged to so Prompt treatment of confirmed or suspected influenza illness with antiviral drugs is recommended for hospitalized patients, for those with severe, complicated, or progressive illness, and for persons at high risk of complications: children